Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26861-26870 Newer>

The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
The Motley Fool October 25, 2007 Alyce Lomax	Deja Vu at Whole Foods Although the FTC lost its bid to block Whole Foods' acquisition of Wild Oats this past summer, and the deal is already completed, the agency is staging a renewed effort.
The Motley Fool October 25, 2007 Brian Lawler	Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note.
The Motley Fool October 25, 2007 Toby Shute	XTO's Ongoing Excellence Another strong quarter from XTO Energy; the low-cost leader in onshore natural gas production saw output rise 24%.
The Motley Fool October 25, 2007 Steven Mallas	Is Monster Still Scary? For the third quarter, Monster delivered the goods on the top line with a nice double-digit revenue gain of 18%, but operating expenses outpaced sales growth.
The Motley Fool October 25, 2007 Toby Shute	Stop, You'll Wake the Nabors! Margins deteriorated in the most recent quarter for Nabors Industries, but the international segment doubled its contribution to operating income.
The Motley Fool October 25, 2007 Brian Lawler	Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down.
The Motley Fool October 25, 2007 Rich Smith	Boeing Blasts Off Revenues grew 12% and net profits leapt 61% for defense contractor Boeing in the third quarter. The company also has an astounding $295 billion worth of future business lined up. Investors, take note.
The Motley Fool October 25, 2007 Rick Aristotle Munarriz	Select Comfort's Worst Nightmare Select Comfort lowers its guidance for the year in advance of quarterly earnings, while rival Tempur-Pedic beats estimates. Investors, take note.
The Motley Fool October 25, 2007 Billy Fisher	WellPoint Well on Its Way Mega-cap health insurance company WellPoint posts a Q3 operating revenue increase of 5.2%; there was more good news regarding growth and buybacks.
<Older 26861-26870 Newer> Return to current articles.